Beimei Pediatric R&D  Center officially inaugurated Beimei R&D center 

On April 23rd, Shenzhen Beimei Pharmaceutical Co., Ltd. announced the opening of the first laboratory of the Beimei Pediatric Medicine Development Center. Starting from meeting the needs of pediatric patients, the newly opened laboratory has produced outstanding scientific research results in the expanding pharmaceutical market with leading research and development strategies, covering the entire pediatric population, and providing safe and secure medicines for Chinese children.

The R & D center is located in Shenzhen Longhua Yifenghua Industrial Park, covering an area of nearly 600 square meters. Despite the impact of the 2019-nCoV, with great efforts, various advanced instruments have been put in place. The R & D center includes liquid phase room, gas phase room, balance room, stability room, high greenhouse, solid preparation room, coating compression room, compounding room, raw materials room and meeting room, office area, etc. The laboratory staff office workspace is separated from each other.

After the R & D laboratory is officially opened, it will focus on the research and development of high-end pediatric preparations such as inhalation solution, granules, dry suspension and oral solution, and design, develop, replicate and create new medicines according to the individual characteristics of children. The establishment of a research and development laboratory by Beimei shows its determination to work for a long time in the field of prescription medicines for children. Pharmaceutical R & D is a long process, from early R & D to R, with a long period of time and huge investment. Beimei has been focusing on common and rare diseases in pediatrics in China.Focus on diseases in areas where clinical needs remain unmet and focus on the clinical value of pediatric medicines. Pediatric Medicine Development Center was established to better explore and accumulate, to serve Chinese pediatric patients, to improve the treatment and improve the lives of pediatric patients.

This is a brand-new beginning for Beimei. As a pharmaceutical company specializing in the field of prescription medicines for children, Beimei will continue to invest in research and development of 2-3 kinds of children's medicines in urgent need every year, and invest in clinical research. Beimei plans to establish a well-known pediatric medicine research and development organization in China within 3-5 years, and strive to become the best authority of pediatric medicine research and development in China and even the world. Beimei will inject fresh and powerful impetus into the development of prescription medicines for children and provide strong scientific and technological support for better service to children patients through their continuous innovation and efforts.